AbbVie Inc. (ABBV): Operating Cash Flow
$19.03B
Year ended 2025-12-31
$19.51B
Trailing 12 months to 2026-06-30
-8.6%
3-year compound annual growth
+1.6%
5-year compound annual growth
+9.7%
10-year compound annual growth
| Period ended | Operating Cash Flow | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $19.03B | +1.2% | 2026-02-20, From 2025-01-01 |
| 2024-12-31 | $18.81B | -17.7% | 2026-02-20, From 2024-01-01 |
| 2023-12-31 | $22.84B | -8.4% | 2026-02-20, From 2023-01-01 |
| 2022-12-31 | $24.94B | +9.5% | 2025-02-14, From 2022-01-01 |
| 2021-12-31 | $22.78B | +29.5% | 2024-02-20, From 2021-01-01 |
| 2020-12-31 | $17.59B | +32.0% | 2023-02-17, From 2020-01-01 |
| 2019-12-31 | $13.32B | -0.8% | 2022-02-18, From 2019-01-01 |
| 2018-12-31 | $13.43B | +34.8% | 2021-02-19, From 2018-01-01 |
| 2017-12-31 | $9.96B | +41.5% | 2020-02-21, From 2017-01-01 |
| 2016-12-31 | $7.04B | -6.6% | 2019-02-27, From 2016-01-01 |
| 2015-12-31 | $7.54B | +112.3% | 2018-02-16, From 2015-01-01 |
| 2014-12-31 | $3.55B | -43.4% | 2017-02-17, From 2014-01-01 |
| 2013-12-31 | $6.27B | -1.2% | 2016-02-19, From 2013-01-01 |
| 2012-12-31 | $6.34B | +1.6% | 2015-02-20, From 2012-01-01 |
| 2011-12-31 | $6.25B | n/a | 2014-02-21, From 2011-01-01 |
Operating Cash Flow at similar companies
| Company | Year ended | Operating Cash Flow | Change YoY |
|---|---|---|---|
| AbbVie Inc. (ABBV) | 2025-12-31 | $19.03B | +1.2% |
| Pfizer Inc (PFE) | 2025-12-31 | $11.70B | -8.2% |
| Merck & Co., Inc. (MRK) | 2025-12-31 | $16.47B | -23.3% |
| Eli Lilly & Co (LLY) | 2025-12-31 | $16.81B | +90.7% |
| Bristol Myers Squibb Co (BMY) | 2025-12-31 | $14.16B | -6.8% |
| Abbott Laboratories (ABT) | 2025-12-31 | $9.57B | +11.8% |
| Johnson & Johnson (JNJ) | 2025-12-28 | $24.53B | +1.1% |
| Teva Pharmaceutical Industries Ltd (TEVA) | 2025-12-31 | $1.65B | +32.2% |
| Regeneron Pharmaceuticals, Inc. (REGN) | 2025-12-31 | $4.98B | +12.6% |
Compare ABBV, PFE, MRK, LLY side by side · Screen every company in Pharmaceutical Preparations ↗